Mia T Minen1, Sarah Corner2, Thomas Berk2, Valeriya Levitan2, Steven Friedman3, Samrachana Adhikari3, Elizabeth B Seng4. 1. Department of Neurology, NYU Langone Health, 550 1st Avenue, New York, NY 10016, USA; Department of Population Health, NYU Langone Health, 550 1st Avenue, New York, NY 10016, USA. Electronic address: Minenmd@gmail.com. 2. Department of Neurology, NYU Langone Health, 550 1st Avenue, New York, NY 10016, USA. 3. Department of Population Health, NYU Langone Health, 550 1st Avenue, New York, NY 10016, USA. 4. Department of Neurology, Yeshiva University Albert Einstein College of Medicine, 1300 Morris Park Ave, The Bronx, NY 10461, United States.
Abstract
INTRODUCTION: Although hand temperature and electromyograph biofeedback have evidence for migraine prevention, to date, no study has evaluated heartrate variability (HRV) biofeedback for migraine. METHODS: 2-arm randomized trial comparing an 8-week app-based HRV biofeedback (HeartMath) to waitlist control. Feasibility/acceptability outcomes included number and duration of sessions, satisfaction, barriers and adverse events. Primary clinical outcome was Migraine-Specific Quality of Life Questionnaire (MSQv2). RESULTS: There were 52 participants (26/arm). On average, participants randomized to the Hearthmath group completed 29 sessions (SD = 29, range: 2-86) with an average length of 6:43 min over 36 days (SD = 27, range: 0, 88) before discontinuing. 9/29 reported technology barriers. 43% said that they were likely to recommend Heartmath to others. Average MSQv2 decreases were not significant between the Heartmath and waitlist control (estimate = 0.3, 95% CI = -3.1 - 3.6). High users of Heartmath reported a reduction in MSQv2 at day 30 (-12.3 points, p = 0.010) while low users did not (p = 0.765). DISCUSSION: App-based HRV biofeedback was feasible and acceptable on a time-limited basis for people with migraine. Changes in the primary clinical outcome did not differ between biofeedback and control; however, high users of the app reported more benefit than low users.
INTRODUCTION: Although hand temperature and electromyograph biofeedback have evidence for migraine prevention, to date, no study has evaluated heartrate variability (HRV) biofeedback for migraine. METHODS: 2-arm randomized trial comparing an 8-week app-based HRV biofeedback (HeartMath) to waitlist control. Feasibility/acceptability outcomes included number and duration of sessions, satisfaction, barriers and adverse events. Primary clinical outcome was Migraine-Specific Quality of Life Questionnaire (MSQv2). RESULTS: There were 52 participants (26/arm). On average, participants randomized to the Hearthmath group completed 29 sessions (SD = 29, range: 2-86) with an average length of 6:43 min over 36 days (SD = 27, range: 0, 88) before discontinuing. 9/29 reported technology barriers. 43% said that they were likely to recommend Heartmath to others. Average MSQv2 decreases were not significant between the Heartmath and waitlist control (estimate = 0.3, 95% CI = -3.1 - 3.6). High users of Heartmath reported a reduction in MSQv2 at day 30 (-12.3 points, p = 0.010) while low users did not (p = 0.765). DISCUSSION: App-based HRV biofeedback was feasible and acceptable on a time-limited basis for people with migraine. Changes in the primary clinical outcome did not differ between biofeedback and control; however, high users of the app reported more benefit than low users.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: James M Fisher; Nils Y Hammerla; Lynn Rochester; Peter Andras; Richard W Walker Journal: Telemed J E Health Date: 2015-07-17 Impact factor: 3.536
Authors: Mia T Minen; Neil A Busis; Steven Friedman; Maya Campbell; Ananya Sahu; Kazi Maisha; Quazi Hossain; Mia Soviero; Deepti Verma; Leslie Yao; Farng-Yang A Foo; Jaydeep M Bhatt; Laura J Balcer; Steven L Galetta; Sujata Thawani Journal: Digit Health Date: 2022-07-17
Authors: Colt Coffman; Deborah Reyes; Mary Catherine Hess; Alec M Giakas; Melinda Thiam; Jason Jonathon Sico; Elizabeth Seng; William Renthal; Charles Rhoades; Guoshuai Cai; X Michelle Androulakis Journal: Neurology Date: 2022-04-25 Impact factor: 11.800